Research Article
Comparing Long-Term Outcomes of Entecavir and Tenofovir Disoproxil Fumarate in Liver Transplant Patients
Table 4
Hazard ratios for outcomes with ENT and TNF.
| | Variable | Crude | PSM | IPTW | | HR (95% CI) | value | HR (95% CI) | value | HR (95% CI) | value |
| | HBV recurrence | 1.20 (0.65 to 2.21) | 0.566 | 1.18 (0.62 to 2.28) | 0.603 | 1.14 (0.57 to 2.28) | 0.705 | | Renal dysfunction | 1.99 (1.47 to 2.68) | <0.001 | 1.70 (1.21 to 2.37) | 0.002 | 1.80 (1.29 to 2.51) | <0.001 | | Patient survival | 0.68 (0.40 to 1.15) | 0.148 | 0.72 (0.41 to 1.23) | 0.226 | 0.62 (0.35 to 1.09) | 0.099 |
|
|
Abbreviations: ENT: entecavir; TDF: tenofovir; CI: Confidence interval; HR: hazard ratio; PSM: propensity score matching; IPTW: inverse probability of treatment weighting.
|
